STOCK TITAN

SCYNEXIS (SCYX) S-3 Filings

SCYX NASDAQ

Here are the S-3 shelf registrations from SCYNEXIS, Inc. (SCYX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow SCYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCYX filings page.

Rhea-AI Summary

SCYNEXIS, Inc. has filed a replacement shelf registration covering up to an aggregate offering amount of $200,000,000 in common stock, preferred stock, debt securities and warrants, individually or in combination, for offerings after effectiveness. All securities registered under the expiring shelf remained unsold as of the new statement’s filing, and SCYNEXIS says no additional securities are being registered. The old shelf is due to expire November 27, 2026; SCYNEXIS may continue issuing and selling securities covered by it until the earlier of the new statement’s effectiveness or 180 days after that date.

Unless an offering-specific supplement states otherwise, net proceeds, if any, are intended for working capital and general corporate purposes; pending use, they would be temporarily invested in short-term, interest-bearing instruments. SCYNEXIS reports a public float of approximately $52.5 million as of November 3, 2026, and states that the value of a public primary offering may not exceed one-third of public float in any 12-month period unless public float subsequently rises to $75.0 million or more.

Rhea-AI Summary

SCYNEXIS, Inc. registered up to 87,000,000 shares of Common Stock for resale by the purchasers in its March-April 2026 private placement (the "Selling Stockholders"). The registration covers 34,750,000 outstanding shares, 8,750,000 Pre-Funded Warrant shares and 43,500,000 Common Warrant shares issuable upon exercise.

The company will not receive proceeds from resales, except for any cash exercises of Pre-Funded Warrants at $0.0001 per share and Common Warrants at $1.20 per share. Shares outstanding were 79,442,633 as of April 1, 2026. The Common Stock last traded at $0.93 on April 30, 2026.